Israeli researchers and their colleagues from the United States developed an antibody-based treatment that empowers the ...

Attivare Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering new treatments for cancer and infectious ...

The company received the R&D award for its pioneering work on Tumor Microenvironment Typing, a comprehensive biomarker for ...

Patient-derived organoids (PDOs) are revolutionizing cancer research, enhancing drug testing and personalized treatment ...

Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...

A growing cancer is shaped by more than just the tumor cells it contains; the tissue around a tumor also alters its biology.

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T ...

The most important takeaway from the study is that these data suggest that CD47 is an attractive target for drug development.

Pancreatic ductal adenocarcinoma (PDAC) is recognized as one of the most lethal cancers, with an estimated five-year survival ...

Researchers say study offers proof-of-concept that targeting how T cells interact with metabolites in their environment can ...